Arvelle Therapeutics - Raised $223M Funding from 11 …

Nov 13, 2024 · Arvelle Therapeutics has raised a total funding of $223M over 2 rounds from 11 investors. Investors include EQT, Life Sciences Partners and 9 others. Their latest funding …

CouponFollow Extension

$223
OFF

Arvelle Therapeutics - Raised $223M Funding From 11 …

6 days from now

Nov 13, 2024 · Arvelle Therapeutics has raised a total funding of $223M over 2 rounds from 11 investors. Investors include EQT, Life Sciences Partners and 9 others. Their latest funding …

tracxn.com

$223
OFF

Arvelle Therapeutics - Company Profile - Tracxn

6 days from now

Aug 17, 2021 · Arvelle Therapeutics - Developer of small molecules for the treatment of partial-onset seizures. Acquired by Angelini Pharma. Raised a total funding of $223M over 2 rounds …

tracxn.com

$43
OFF

Arvelle Therapeutics - Crunchbase Company Profile

6 days from now

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solution. ... 1,647 Number of Organizations • $43.2B Total Funding Amount • 4,964 Number of …

crunchbase.com

32%
OFF

Arvelle Announces Closing Of Final Tranche Of $42.7m Funding

6 days from now

May 27, 2020 · The final tranche of $42.7m, representing 32% of the initial total Series A commitment of $133.3m, along with $74.5m in previously funded product financing, brings the …

londonlovesbusiness.com

$42700000
OFF

Series A - Arvelle Therapeutics - 2020-05-27 - Crunchbase

6 days from now

Arvelle Therapeutics raised $42700000 on 2020-05-27 in Series A. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log In. …

crunchbase.com

$207
OFF

Arvelle Therapeutics Stock Price, Funding, Valuation, …

6 days from now

Jan 4, 2021 · Funding, Valuation & Revenue. 4 Fundings. Arvelle Therapeutics has raised $207.8M over 4 rounds.. Arvelle Therapeutics's latest funding round was a Acquired for on …

cbinsights.com

$223
OFF

Arvelle Therapeutics - Company Profile - Tracxn

6 days from now

Arvelle Therapeutics - Developer of small molecules for the treatment of partial-onset seizures. Acquired by Angelini Pharma. Raised a total funding of $223M over 2 rounds from 11 …

tracxn.com

$221
OFF

Arvelle Therapeutics (Switzerland) Funding: $221.8M

6 days from now

Oct 24, 2024 · Arvelle carries forward the European rights to cenobamate, an anti-epileptic drug for partial-onset...

medicalstartups.org

$223
OFF

59 Competitors And Alternatives In Nov 2024 - Tracxn

6 days from now

Nov 5, 2024 · Funding $223M. Location Zug (Switzerland) ... EpilepsyGTx's competitors have raised a total of $2.59B funding across 51 funding rounds. See the ... Arvelle Therapeutics. …

tracxn.com

$223
OFF

Arvelle Therapeutics - Raised $223M Funding From 11 …

6 days from now

Arvelle Therapeutics has raised a total funding of $223M over 2 rounds from 11 investors. Investors include EQT, Eight Roads Ventures and 9 others. Their latest funding round was of …

tracxn.com

$179146724
OFF

Series A - Arvelle Therapeutics - 2019-02-18 - Crunchbase

6 days from now

Arvelle Therapeutics raised $179146724 on 2019-02-18 in Series A. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log In. …

crunchbase.com

FAQs about Arvelle Therapeutics - Raised $223M Funding from 11 … Coupon?

When did Arvelle Therapeutics close?

Arvelle Therapeutics closed its last funding round on May 27, 2020 from a Series A round. Who are Arvelle Therapeutics 's competitors? Alternatives and possible competitors to Arvelle Therapeutics may include Reata Pharmaceuticals , Lightcast Discovery , and Cytokinetics. ...

Who bought Arvelle Therapeutics?

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. Arvelle Therapeutics was acquired by Angelini Pharma for $960M on Jan 4, 2021. This deal was done in Cash. Where is Arvelle Therapeutics 's headquarters? ...

Who is Arvelle Therapeutics?

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solution. View contacts for Arvelle Therapeutics to access new leads and connect with decision-makers. Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders. ...

What are alternatives to Arvelle Therapeutics?

Alternatives and possible competitors to Arvelle Therapeutics may include Reata Pharmaceuticals , Lightcast Discovery , and Cytokinetics. Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solution. ...

Does SK Biopharmaceuticals own Arvelle Therapeutics?

SK Biopharmaceuticals, a global innovative pharmaceutical company listed on the Korea Stock Exchange, announced that it has agreed to sell its 12 percent stake in Arvelle Therapeutics to Angelini Pharma. ...

Who is the legal counsel for Arvelle & Angelini Pharma?

For Arvelle, Centerview Partners UK LLP is acting as sole financial advisor and Sidley Austin LLP is acting as legal counsel and NautaDutilh N.V. is also providing legal counsel. For Angelini Pharma, White & Case (Europe) LLP is acting as legal counsel, with the support of KMPG for the due diligence Tax & Accounting. ...